

Pharmacy Prior Authorization

Clinical Guideline – Cytokines and Cell Adhesion Molecule (CAM) Antagonists

Actemra (tocilizumab)	Ilaris (canakinumab)	Simponi (golimumab)
Amjevita Auto-Injector	Ilumya (tildrakizumab)	Simponi Aria (golimumab)
(adalimumab-atto)	Inflectra (infliximab-dyyb)	Stelara (ustekinumab)
Amjevita Prefilled Syringe	Kevzara (sarilumab)	Skyrizi (risankizumab)
(adalimumab-atto)	Kineret (anakinra)	Taltz (ixekizumab)
Arcalyst (rilonacept)	Olumiant (baricitinib)	Tremfya (guselkumab)
Avsola (infliximab-axxq)	Orencia (abatacept)	Tysabri (natalizumab)
Cimzia (certolizumab)	Remicade (infliximab)	Xeljanz (tofacitinib)
Cosentyx (secukinumab)	Renflexis (infliximab-adba)	Xeljanz XR (tofacitinib)
Enbrel (etanercept)	Rinvoq (upadacitinib)	
Entyvio (vedolizumab)	Siliq (brodalumab)	
Humira (adalimumab)		

Preferred Agents: ENBREL, HUMIRA, and KEVZARA

Non-Preferred Anti-Tumor Necrosis Factors (TNFs):

Amjevita Auto-Injector/Prefilled Syringe, Avsola, Cimzia, Remicade, Inflectra, Renflexis and Simponi require trial and failure of ALL preferred agents, where indicated, in addition to all other clinical criteria.

Non-Preferred Cytokines and Cell Adhesion Molecule (CAM) Antagonists:

Require trial and failure of ONE preferred anti-TNF (Enbrel or Humira) OR Kevzara, where indicated, in addition to all other clinical criteria.

NOTE: Authorization criteria for Tysabri in multiple sclerosis are included in the Multiple Sclerosis agents Prior Authorization guideline.

General Authorization Guidelines for All Medications and Indications:

- Member is not on another Cytokine or Cell Adhesion Molecule (CAM) Antagonist.
- Prescribed by an appropriate specialist based on indication.
- Member has been evaluated for, and given appropriate vaccinations, as recommended per Center for Disease Control for member risk factors.
- Member has been screened for tuberculosis. If screening was positive for latent tuberculosis, member has received treatment for latent tuberculosis (exception: Tysabri).
- Prescribed dose is Food and Drug Administration (FDA) approved for indication. Doses above Food and Drug Administration (FDA) approved labeling will not be authorized. Quantity limits exist.
- For Anti-Tumor Necrosis Factors only: Member does not have New York Heart Association (NYHA) class III or IV Congestive Heart Failure.
- For Anti-Tumor Necrosis Factors, Xeljanz, Xeljanz XR, Actemra, Ilaris, Orencia, and Rinvoq: Member has been screened for Hepatitis B. If member has active or chronic Hepatitis B, member is receiving appropriate antiviral treatment (initiation is not recommended with Rinvoq for those with active Hepatitis B).
- For Entyvio and Tysabri: Will be used as monotherapy and not in combination with antineoplastic, immunosuppressive, or immunomodulating agents (for example, azathioprine, 6-mercaptopurine cyclosporine, methotrexate, tumor necrosis factors (TNF) inhibitors)

Additional Criteria Based on Indication:

Pharmacy Prior Authorization

Clinical Guideline – Cytokines and Cell Adhesion Molecule (CAM) Antagonists

- **Rheumatoid Arthritis: Amjevita, Enbrel, Humira, Actemra, Avsola, Cimzia, Inflectra, Kevzara, Kineret, Olumiant, Orencia, Remicade, Renflexis, Rinvoq, Simponi, Simponi Aria, Xeljanz, Xeljanz XR**
 - Member is 18 years of age or older
 - Diagnosis of active moderate to severe Rheumatoid Arthritis (for example, swollen, tender joints with limited range of motion) confirmed by positive results for the following:
 - Rheumatoid factor (RF) and/or anti-citrullinated peptide/protein antibody (ACPA), such as Anti-cyclic citrullinated peptide (anti-CCP)
 - Elevated levels of C-reactive protein (CRP) or the erythrocyte sedimentation rate (ESR)
 - Documented inadequate response to a three-month trial of methotrexate. If there is an intolerance or contraindication to methotrexate, member can use sulfasalazine, leflunomide or hydroxychloroquine
- **Systemic Juvenile Idiopathic Arthritis: Amjevita, Enbrel, Humira, Orencia (subcutaneous/intravenous)**
 - Member is 2 years of age or older - Amjevita, Enbrel, Humira, and Orencia (subcutaneous)
 - Member is 6 years -of age or older - Orencia intravenous
 - Documentation of one of the following:
 - Has had a 1-month trial of nonsteroidal anti-inflammatory drugs (NSAIDs) or inadequate response to intra-articular corticosteroid injection followed by a 1-month trial of Kineret
 - Has had a three-month treatment with methotrexate or leflunomide
- **Systemic Juvenile Idiopathic Arthritis: Kineret, Actemra, Ilaris**
 - Member is 2 years of age or older
 - Ilaris only: Member weighs at least 7.5kg
 - Documentation member meets one of the following:
 - Has had a 1-month trial of nonsteroidal anti-inflammatory drugs (NSAIDs)
 - Has had an inadequate response to a 2-week trial of corticosteroids
 - Has had a three-month treatment with methotrexate or leflunomide
 - Note: Member does not require trial of formulary agents
- **Adult-Onset Still's Disease: Ilaris**
 - Member is 2 years of age or older
 - Member weighs at least 7.5kg
 - Documentation member meets one of the following:
 - Has had a 1-month trial of nonsteroidal anti-inflammatory drugs (NSAIDs)
 - Has had an inadequate response to a 2-week trial of corticosteroids
 - Has had a three-month treatment with methotrexate or leflunomide
- **Polyarticular Juvenile Idiopathic Arthritis: Amjevita, Enbrel, Humira, Orencia (intravenous/subcutaneous), Actemra, Xeljanz**
 - Member is 2 years of age or older - Amjevita, Enbrel, Humira, Orencia (subcutaneous), Actemra, and Xeljanz
 - Member is 6 years of age or older - Orencia (intravenous)
 - Documented inadequate response to a three-month trial of methotrexate
 - If member has an intolerance, or contraindication to methotrexate, a documented trial of leflunomide or sulfasalazine for 3 months is required
- **Oligoarticular Juvenile Idiopathic Arthritis: Amjevita, Enbrel, Humira**

NOTE: Anti-Tumor Necrosis Factors are not standard therapy for most members, as this is usually a self-limiting condition that rarely becomes chronic

 - Member is 2 years of age or older

Pharmacy Prior Authorization**Clinical Guideline – Cytokines and Cell Adhesion Molecule (CAM) Antagonists**

- Documented inadequate response or intolerable side effect to 2 Non-Steroidal Anti-Inflammatory Drugs, or member has a contraindication to Non-steroidal Anti-Inflammatory Drugs
- Documented inadequate response, or intolerable side effect to a 3-month trial of methotrexate
- If member has an intolerance, or contraindication to methotrexate, a documented trial of leflunomide or sulfasalazine for 3 months is required
- **Cryopyrin-Associated Periodic Syndromes: Kineret**
 - Diagnosis of Cryopyrin-Associated Periodic Syndromes, including neonatal-onset multisystem inflammatory disease, Familial Cold Auto Inflammatory Syndrome, or Muckle-Wells Syndrome
 - NOTE: Member does not require trial of formulary agents
- **Cryopyrin-Associated Periodic Syndromes: Arcalyst, Ilaris**
 - Member is 4 years of age or older and weighs at least 15 kilograms - Ilaris
 - Member is 12 years of age or older - Arcalyst
 - Diagnosis of Cryopyrin-Associated Periodic Syndromes with one of the following subtypes
 - Familial Cold Auto Inflammatory Syndrome
 - Muckle-Wells syndrome
 - Member had a three-month trial of Kineret (Kineret is Non-Formulary and will require a Prior Authorization)
 - NOTE: Member does not require trial of formulary agents
- **Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS): Ilaris**
 - Member is 2 years of age or older
 - Member has chronic or recurrent disease activity defined as 6 flares per year
 - Physician's Global Assessment (PGA) score greater than or equal to 2 or C-reactive protein (CRP) greater than 10 mg/L
 - NOTE: Member does not require trial of formulary agents
- **Hyperimmunoglobulin D Syndrome/Mevalonate Kinase Deficiency (HIDS/MKD): Ilaris**
 - Member is 2 years of age or older
 - Member has history or greater than or equal to 3 febrile acute flares within a 6-month period
 - Physician's Global Assessment (PGA) score greater than or equal to 2 or C-reactive protein (CRP) greater than 10 mg/L
 - NOTE: Member does not require trial of formulary agents
- **Familial Mediterranean Fever: Ilaris**
 - Member is 2 years of age or older
 - C-reactive protein (CRP) greater than 10 mg/L
 - Member has history of at least one flare per month
 - Documented inadequate response, intolerance, or contraindication to colchicine at maximum indicated dose (claims history to support compliance or adherence).
 - NOTE: Member does not require trial of formulary agents
- **Giant Cell Arteritis: Actemra**
 - Member is 18 years of age or older
 - Documented inadequate response, intolerance, or contraindication with glucocorticoids (for example prednisone, methylprednisolone).
 - If member has an intolerance, or contraindication to glucocorticoids, a trial of methotrexate or cyclophosphamide is required

Pharmacy Prior Authorization

Clinical Guideline – Cytokines and Cell Adhesion Molecule (CAM) Antagonists

- Actemra will be used in combination with a tapering course of glucocorticoids
 - NOTE: Member does not require trial of formulary agents
 - **Ankylosing Spondylitis: Amjevita, Enbrel, Humira, Avsola, Cimzia, Cosentyx, Inflectra, Remicade, Renflexis, Simponi, Simponi Aria, Taltz, Xeljanz, Xeljanz XR**
 - Member is 18 years of age or older
 - Documented inadequate response to a one-month trial of two Non-Steroidal Anti-Inflammatory Drugs, or member has a contraindication or intolerance to oral Non-Steroidal Anti-Inflammatory Drugs
 - **Non-Radiographic Axial Spondyloarthritis: Cosentyx, Taltz**
 - Member is 18 years of age or older
 - Documented inadequate response to a one-month trial of two Non-Steroidal Anti-Inflammatory Drugs, or member has a contraindication or intolerance to oral Non-Steroidal Anti-Inflammatory Drugs
 - NOTE: Member does not require trial of formulary agents
 - **Enthesitis-Related Arthritis: Cosentyx**
 - Member is 4 years of age or older
 - Documented inadequate response, or intolerable side effect to a 3-month trial of methotrexate or sulfasalazine
 - NOTE: Member does not require trial of formulary agents
 - **Psoriatic Arthritis: Amjevita, Enbrel, Humira, Avsola, Cimzia, Cosentyx, Inflectra, Orencia, Remicade, Renflexis, Rinvoq, Simponi, Simponi Aria, Skyrizi, Stelara, Taltz, Tremfaya, Xeljanz, Xeljanz XR**
 - Member is 18 years of age or older - Amjevita, Enbrel, Humira, Avsola, Cimzia, Inflectra, Orencia, Remicade, Renflexis, Rinvoq, Simponi, Simponi Aria, Skyrizi, Stelara, Taltz, Tremfaya, Xeljanz, Xeljanz XR
 - Member is 2 years of age or older - Cosentyx
 - Documentation of one of the following:
 - Member has active Psoriatic Arthritis, and an inadequate response to a three-month trial of methotrexate, or if member has intolerance, or contraindication to methotrexate, there was a three-month trial of sulfasalazine, or leflunomide
 - Member has predominantly axial disease or active enthesitis/dactylitis, and inadequate response to one-month trial of two Non-Steroidal Anti-Inflammatory Drugs, or member has a contraindication or intolerance to oral Non-Steroidal Anti-Inflammatory Drugs
- Note:
- Member should continue use of Non-Steroidal Anti-Inflammatory Drugs as needed for bridging or adjunctive therapy when starting Disease-Modifying Anti-Rheumatic Drug
 - Cosentyx and Stelara should be considered if member has contraindication to Tumor Necrosis Factor Inhibitors (for example, Heart failure, Multiple Sclerosis), where Tumor Necrosis Factor Inhibitor is indicated
- **Plaque Psoriasis: Amjevita, Enbrel, Humira, Avsola, Cimzia, Cosentyx, Ilumya, Inflectra, Remicade, Renflexis, Siliq, Tremfya, Stelara, Taltz, Skyrizi**
 - Member is 18 years of age or older - Amjevita, Humira, Avsola, Cimzia, Ilumya, Inflectra, Remicade, Renflexis, Siliq, Skyrizi, Tremfya
 - Member is 4 years of age or older - Enbrel
 - Member is 6 years of age or older – Cosentyx, Stelara, Taltz
 - Documented inadequate response, intolerance, or contraindication, to at least one oral systemic therapy such as methotrexate, or cyclosporine for 3 months or more
 - Member has one of the following:

Last Update: 10/2016, 05/08/2017, 2/2018, 6/1/2018, 6/3/2019, 11/26/2019, 9/2021, 3/2022, 3/20/2023

Effective: 5/1/2023

Pharmacy Prior Authorization

Clinical Guideline – Cytokines and Cell Adhesion Molecule (CAM) Antagonists

- More than 10% of Body Surface Area is affected
- Less than 10% Body Surface Area is affected, but involves sensitive areas (for example, hands, feet, face or genitals) that interfere with daily activities
- Psoriasis Area and Severity Index score more than 10
- Phototherapy (PUVA (psoralen ultraviolet type A), UVB (ultraviolet type B)) has been ineffective
- For Siliq: Mental health evaluation has been completed by prescriber or psychiatrist, if member has history of prior suicide attempt, bipolar disorder or depressive disorder
- **Ulcerative Colitis: Amjevita, Humira, Avsola, Entyvio, Inflectra, Remicade, Renflexis, Rinvoq, Simponi, Stelara, Xeljanz, Xeljanz XR**
 - Member is 18 years of age or older - Amjevita, Entyvio, Inflectra, Rinvoq, Simponi, Stelara, Xeljanz, Xeljanz XR
 - Member is 6 years of age or older – Avsola, Remicade, Renflexis
 - Member is 5 years of age or older – Humira
 - Documentation of one of the following:
 - Inadequate response, or intolerable side effects, to systemic corticosteroids or 5-aminosalicylates (for example mesalamine, Apriso, Asacol, Pentasa)
 - Member has been hospitalized for acute severe ulcerative colitis and failed to respond to 3 – 5 days of intravenous corticosteroids
- **Crohn's Disease: Amjevita, Humira, Avsola, Cimzia, Entyvio, Inflectra, Remicade, Renflexis, Stelara, Tysabri**
 - Member is 18 years of age or older - Cimzia, Entyvio, Stelara, Tysabri
 - Member is 6 years of age or older – Amjevita, Humira, Avsola, Inflectra, Remicade, Renflexis
 - Documentation of one of the following:
 - Inadequate response, or intolerable side effects, to systemic corticosteroids, thiopurines (for example azathioprine), or methotrexate
 - Medication is being used for the treatment of fistulizing disease
- **Hidradenitis Suppurativa (Acne Inversa): Amjevita, Humira**
 - Member is 12 years of age or older – Humira
 - Member is 18 years of age or older - Amjevita
 - Member has moderate to severe disease (Hurley stage II-III)
 - Documentation of trial and failure of a 90-day treatment with oral antibiotics (for example, doxycycline, minocycline, or clindamycin with rifampin)
- **Uveitis: Humira**
 - Member is 2 years of age or older
 - Intermediate, posterior, or pan uveitis is not caused by infection
 - Documented inadequate response, or intolerable side effect, with any of the following:
 - Corticosteroids, methotrexate, azathioprine, mycophenolate, cyclosporine, tacrolimus, or medications are not appropriate
- **Cytokine Release Syndrome: Actemra Intravenous Only**
 - Member is 2 years of age or older
 - Member has Grade three or four of severe or life-threatening diagnosis due to chimeric antigen receptor-T cell therapy
 - NOTE: Member does not require trial of formulary agents
- **Deficiency of Interleukin-1 Receptor Antagonist (DIRA) -- Treatment: Kineret**

Pharmacy Prior Authorization**Clinical Guideline – Cytokines and Cell Adhesion Molecule (CAM) Antagonists**

- Member has a genetically confirmed diagnosis of DIRA with documentation of IL1RN mutation status
- NOTE: Member does not require trial of formulary agents
- **Deficiency of Interleukin-1 Receptor Antagonist (DIRA) – Maintenance of Remission: Arcalyst**
 - Member has a genetically confirmed diagnosis of DIRA with documentation IL1RN loss-of-function mutations
 - Medication will be used after achievement of remission using Kineret
 - Member weighs 10kg or more
 - NOTE: Member does not require trial of formulary agents
- **Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): Actemra subcutaneous only**
 - Member is 18 years of age or older
 - Documentation showing the diagnosis was confirmed by a high-resolution computed tomography (HRCT) study of the chest
 - NOTE: Member does not require trial of formulary agents
- **Acute Graft Versus Host Disease: Orencia**
 - Member is 2 years of age or older
 - Medication will be used for prophylaxis of acute graft versus host disease (aGVHD) in combination with a calcineurin inhibitor and methotrexate
 - Member is undergoing hematopoietic stem cell transplantation (HSCT) from a matched or 1 allele-mismatched unrelated donor
 - NOTE: Member does not require trial of formulary agents and approvals will be for 1 month. Each approval must meet initial criteria.
- **Recurrent Pericarditis: Arcalyst**
 - Member is 12 years of age or older
 - Member has had at least two episodes of pericarditis
 - Member has failed therapy with multiple attempts at therapy with colchicine plus a Non-Steroidal Anti-Inflammatory Drug and has refractory, corticosteroid-dependent disease
 - NOTE: Member does not require trial of formulary agents
- **Atopic Dermatitis: Rinvoq**
 - Member is 12 years of age or older
 - Documentation showing member has atopic dermatitis evidenced by one of the following:
 - Validated Investigator's Global Assessment (vIGA-AD) score greater than or equal to 3
 - Eczema Area and Severity Index (EASI) score greater than or equal to 16
 - A minimum body surface area (BSA) involvement of greater than or equal to 10%
 - Member had inadequate response, intolerable side effect, or contraindication to all the following therapies:
 - Two preferred (medium to very high potency) topical corticosteroids
 - For example, triamcinolone, clobetasol, mometasone, betamethasone, fluocinonide
 - OR
 - One preferred low potency topical corticosteroid, for sensitive areas
 - For example, face, neck, and other skin folds
 - One preferred topical calcineurin inhibitor such as tacrolimus
 - One oral systemic therapy, if appropriate
 - NOTE: Member does not require trial of formulary agents

Pharmacy Prior Authorization**Clinical Guideline – Cytokines and Cell Adhesion Molecule (CAM) Antagonists****Initial Approval: 6 months****Renewal Approval: 6 months**

- Requires: Documentation indicating member has shown improvement in signs and symptoms of disease

Dosing and administration:

- **Humira/Amjevita:**

- Hidradenitis suppurativa:
 - Adults: 160 mg day 1, followed by 80 mg day 15 (6 syringes/28 days) for induction period, thereafter 40 mg once a week starting day 29 (4 syringes/28 days)
 - Children 12-17 years old:
 - >60 kg or more: 160 mg day 1, followed by 80 mg day 15 (6 syringes/28 days) for induction period, thereafter 40 mg once a week starting day 29 (4 syringes/28 days)
 - 30-59 kg: 80 mg on day 1, then maintenance treatment of 40 mg once every other week starting on day 8.
- Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis:
 - Two syringes/pens per 28 days
 - In the treatment of RA some patients may derive additional benefit from the use of 4 syringes/pens per 28 days
- Crohn's, Ulcerative Colitis:
 - Adults: Six syringes/pens in initial 28 days and two syringes/pens per 28 days after induction period
 - Crohn's in Children:
 - 17-39kg: 120 mg in the initial 28 days then 20mg every other week
 - 40 kg or more: 240 mg in the initial 28 days then 40 mg every other week
 - UC in Children:
 - 20 kg to 39 kg: 160 mg in the initial 28 days then 40 mg every other week or 20 mg every week
 - 40 kg or more: 320 mg in the initial 28 days then 80 mg every other week or 40 mg every week
- Psoriasis (Humira and Amjevita) and Adult Uveitis (Humira only)
 - Four syringes/pens in the initial 28 days
 - Two syringes/pens per 28 days after induction period
- Juvenile Idiopathic Arthritis (Humira and Amjevita) and Pediatric Uveitis (Humira only):
 - Children 2 years of age and older:
 - 30 kg or more: 40 mg every other week
 - 15-29 kg: 20 mg every other week
 - 10-14 kg: 10 mg every other week

- **Enbrel**

- Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, and Juvenile Idiopathic Arthritis:
 - Four, 50mg syringes, OR eight 25mg syringes per 28 days
- Psoriasis:
 - 8, 50mg syringes per 28 days for the initial 3 months
 - 4, 50mg syringes per 28 days after induction period

- **Actemra Subcutaneous**

Last Update: 10/2016, 05/08/2017, 2/2018, 6/1/2018, 6/3/2019, 11/26/2019, 9/2021, 3/2022, 3/20/2023

Effective: 5/1/2023

Pharmacy Prior Authorization

Clinical Guideline – Cytokines and Cell Adhesion Molecule (CAM) Antagonists

- Rheumatoid Arthritis:
 - Weight <100kg: Two syringes per 28 days. Max dose is 4 syringes per 28 days
 - Weight ≥100kg: Four syringes per 28 days
- Giant Cell Arteritis:
 - 162mg once weekly in combination with a tapering course of glucocorticoids
 - 162mg once every other week in combination with a tapering course of glucocorticoids may be prescribed based on clinical presentation.
- Systemic Sclerosis-Associated Interstitial Lung Disease
 - 162mg once weekly
- Polyarticular Juvenile Idiopathic Arthritis:
 - Weight <30kg: 162mg once every 3 weeks
 - Weight ≥30kg: 162mg every 2 weeks
- Systemic Juvenile Idiopathic Arthritis:
 - Weight <30kg: 162mg every 2 weeks
 - Weight ≥30kg: 162mg once weekly
- **Actemra intravenous**
 - Rheumatoid Arthritis: 4 to 8mg/kg every 28 days
 - Giant Cell Arteritis: 6mg/kg every 28 days with a tapering course of glucocorticoids
 - Polyarticular Juvenile Idiopathic Arthritis:
 - Weight <30kg: 10mg/kg every 28 days
 - Weight ≥30kg: 8mg/kg every 28 days
 - Systemic Juvenile Idiopathic Arthritis:
 - Weight <30kg: 12mg/kg every 2 weeks
 - Weight ≥30kg: 8mg/kg every 2 weeks
 - Cytokine Release Syndrome:
 - 30 kg or more: 8 mg/kg for one dose, up to 3 additional doses if no clinical improvement (max dose 800 mg)
 - Less than 30 kg: 12 mg/kg for one dose, up to 3 additional doses if no clinical improvement (max dose 800 mg)
- **Arcalyst**
 - Cryopyrin-Associated Periodic Syndromes, Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, Recurrent Pericarditis
 - 5 vials in the initial 28 days then 4 vials every 28 days
 - Deficiency of IL-1 Receptor Antagonist
 - 8 vials every 28 days
- **Avsola**
 - Rheumatoid Arthritis:
 - 3mg/kg at week 0, 2 and 6, then every 8 weeks thereafter. Max dose 10mg/kg every 8 weeks or 3mg/kg every 4 weeks.
 - Crohns:
 - 5mg/kg at week 0, 2, 6, then every 8 weeks thereafter. Max dose 10mg/kg every 8 weeks
 - Ulcerative Colitis, Psoriatic Arthritis, Psoriasis:
 - 5mg/kg at week 0, 2, 6, then every 8 weeks thereafter
 - Ankylosing Spondylitis:
 - 5mg/kg at week 0, 2, 6, then every 6 weeks thereafter

Last Update: 10/2016, 05/08/2017, 2/2018, 6/1/2018, 6/3/2019, 11/26/2019, 9/2021, 3/2022, 3/20/2023

Effective: 5/1/2023

Pharmacy Prior Authorization

Clinical Guideline – Cytokines and Cell Adhesion Molecule (CAM) Antagonists

- **Cimzia**
 - Eight vials/syringes per 28 days
- **Cosentyx**
 - Ankylosing Spondylitis and Psoriatic Arthritis:
 - Five syringes/pens in the initial 28 days
 - One syringe/pen per 28 days after induction period; two syringes/pens per 28 days may be used for those who continue to have active disease
 - Psoriasis
 - Ten syringes/pens in the initial 28 days
 - Two syringes/pens per 28 days after induction period
 - Non-Radiographic Axial Spondyloarthritis and Enthesitis-Related Arthritis:
 - Five syringes/pens in the initial 28 days
 - One syringe/pen per 28 days after induction period
- **Entyvio**
 - Crohns and Ulcerative Colitis:
 - 300 mg at weeks 0, 2, 6 for induction (3 vials/6 weeks), then 300 mg (1 vial) every 8 weeks after induction period
- **Ilaris**
 - Cryopyrin-Associated Periodic Syndromes (>40 kg):
 - 150mg every 8 weeks, one vial per 56 days
 - Cryopyrin-Associated Periodic Syndromes (≤40 kg):
 - 2mg/kg every 8 weeks, one vial per 56 days. Dose may be increased to 3mg/kg given every 8 weeks
 - Systemic Juvenile Idiopathic Arthritis and Still's Disease:
 - 4mg/kg (max 300mg) every 4 weeks
 - QLL for doses <180mg: One vial per 28 days
 - QLL for doses >180mg: Two vials per 28 days
 - Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS), Hyperimmunoglobulin D Syndrome/Mevalonate Kinase Deficiency (HIDS/MKD), and Familial Mediterranean Fever (FMF):
 - >40 kg: 150mg every 4 weeks, one vial per 28 days
 - ≤40kg: 2mg/kg every 4 weeks, one vial per 28 days. Dose may be increased to 4mg/kg every 4 weeks.
- **Ilumya**
 - Plaque Psoriasis:
 - 100 mg (two syringes) per 28 days for the induction period; then 100 mg (one syringe) every 12 weeks after the induction period.
- **Kevzara**
 - Rheumatoid Arthritis:
 - 200mg SC every 2 weeks, two syringes per 28 days
- **Kineret**
 - Rheumatoid Arthritis, Juvenile Idiopathic Arthritis:
 - One syringe per day
 - Cryopyrin-Associated Periodic Syndromes and Deficiency of Interleukin-1 Receptor Antagonist:
 - Maximum dose of 8mg/kg/day

Pharmacy Prior Authorization

Clinical Guideline – Cytokines and Cell Adhesion Molecule (CAM) Antagonists

- **Olumiant**
 - Rheumatoid Arthritis:
 - One tablet (2mg) daily, 28 tablets per 28 days
- **Orencia IV:**
 - Rheumatoid Arthritis, Psoriatic Arthritis:
 - Weight <60kg: 4 vials for the initial 28 days and 2 vials per 28 days thereafter
 - Weight 60-100kg: 6 vials for the initial 28 days and 3 vials per 28 days thereafter
 - Weight >100kg: 8 vials for the initial 28 days and 4 vials per 28 days thereafter
 - Juvenile Idiopathic Arthritis:
 - Weight <75kg: 6 vials for the initial 28 days and 3 vials per 28 days thereafter
 - Weight 75 - 100kg: 6 vials for the initial 28 days and 3 vials per 28 days thereafter
 - Weight >100kg: 8 vials for the initial 28 days and 4 vials per 28 days thereafter
 - Acute Graft Versus Host Disease:
 - Children 2 to less than 6 years old: 15mg/kg on Day (-1), followed by 12mg/kg on Days 5, 14, and 28
 - 6 years and older: 16 vials per 30 days. 4 vials on Day (-1), followed by 4 vials each on Days 5, 14, and 28
- **Orencia Subcutaneous**
 - Rheumatoid Arthritis:
 - 125 mg once a week
 - Polyarticular juvenile idiopathic arthritis:
 - Children and adolescents 2 years and older weighing greater 50 kg: 125 mg subcutaneously once a week
 - Children and adolescents 2 years and older weighing 25 kg to less than 50 kg: 87.5 mg subcutaneously once a week
 - Children and adolescents 2 years and older weighing 10kg to 25 kg: 50 mg subcutaneously once a week
 - Psoriatic Arthritis:
 - 125 mg subcutaneously once a week
- **Remicade/Inflectra/Renflexis/Avsola**
 - Rheumatoid Arthritis:
 - 3mg/kg at week 0, 2 and 6, then every 8 weeks thereafter. Max dose 10mg/kg every 8 weeks or 3mg/kg every 4 weeks.
 - Crohns:
 - 5mg/kg at week 0, 2, 6, then every 8 weeks thereafter. Max dose 10mg/kg every 8 weeks
 - Ulcerative Colitis, Psoriatic Arthritis, Psoriasis:
 - 5mg/kg at week 0, 2, 6, then every 8 weeks thereafter
 - Ankylosing Spondylitis:
 - 5mg/kg at week 0, 2, 6, then every 6 weeks thereafter
- **Rinvoq**
 - Atopic Dermatitis, Rheumatoid Arthritis, Psoriatic Arthritis, and Ulcerative Colitis:
 - 28 tablets per 28 days
- **Siliq**
 - Psoriasis:

Pharmacy Prior Authorization**Clinical Guideline – Cytokines and Cell Adhesion Molecule (CAM) Antagonists**

- Three (210mg) syringes for first 28 days; Two syringes per 28 days thereafter. Treatment should be discontinued if inadequate response after 12 to 16 weeks

- **Simponi**

- Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis:
 - One, 50mg syringe per 28 days
- Ulcerative Colitis:
 - Three, 100mg syringes allowed in the initial 54 days
 - One, 100mg syringe per 28 days after induction period

- **Simponi Aria**

- Rheumatoid Arthritis:
 - 2mg/kg at week 0 and 4, then every 8 weeks thereafter

- **Skyrizi**

- Plaque psoriasis and Psoriatic Arthritis:
 - 4 syringes in the initial 28 days
 - 2 syringes per 84 days after induction period

- **Stelara**

- Psoriasis adults:
 - Weight ≤ 100 kg: One, 45mg syringe per 28 days for initial 2 months; then one, 45mg syringe per 84 days
 - Weight > 100 kg: One, 90mg syringe per 28 days for initial 2 months; then one, 90mg syringe per 84 days
- Psoriasis pediatrics:
 - Weight < 60 kg: One, 45mg syringe per 28 days for initial 2 months; then one, 45mg syringe per 84 days
 - Weight 60 to 100kg: One, 45mg syringe per 28 days for initial 2 months; then one, 45mg syringe per 84 days
 - Weight > 100 kg: One, 90mg syringe per 28 days for initial 2 months; then one, 90mg syringe per 84 day
- Psoriatic Arthritis:
 - One, 45mg syringe per 28 days for initial 2 months; then 1, 45mg syringe per 84 days
- Ulcerative Colitis, Crohn's:
 - Initial:
 - Up to 55kg: 260 mg (2, 130mg vials)
 - 55kg $< \text{to} \leq 85$ kg: 390 mg (3, 130mg vials)
 - > 85 kg: 520 mg (4, 130mg vials)
 - Maintenance: One, 90mg syringe per 56 days starting 8 weeks after initial dose

- **Taltz**

- Psoriasis:
 - Four syringes in the first 28 days
 - Two syringes per 28 days for months 2 and 3
 - One syringe per 28 days after induction
- Psoriatic Arthritis and Ankylosing Spondylitis:
 - Two syringes in the first 28 days then one syringe per 28 days
- Non-radiographic Axial Spondyloarthritis:
 - One syringe per 28 days

Pharmacy Prior Authorization

Clinical Guideline – Cytokines and Cell Adhesion Molecule (CAM) Antagonists

- **Tremfya**
 - Plaque psoriasis and psoriatic arthritis:
 - Two syringes or injectors in the initial 28 days then one syringe or injector every 8 weeks
- **Tysabri**
 - Crohn's:
 - 1 vial per 28 days
- **Xeljanz**
 - Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis:
 - Two (5 mg) tablets per day
 - Ulcerative Colitis:
 - 10 mg twice a day for 8 weeks, then 5 mg or 10 mg twice a day
 - Polyarticular Juvenile Idiopathic Arthritis
 - 9 kg ≤ to <20 kg: 3.2 mg (3.2 mL oral solution) twice daily
 - 20 kg ≤ to < 40 kg: 4 mg (4 mL oral solution) twice daily
 - ≥ 40 kg: 5 mg (one 5 mg tablet or 5 mL oral solution) twice daily
- **Xeljanz XR**
 - Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis:
 - One 11 mg tablet per day
 - Ulcerative Colitis:
 - One 22 mg tablet per day for 8 weeks, then 11 mg or 22 mg once a day

Examples of Contraindications to Methotrexate:

- Alcoholism, alcoholic liver disease or other chronic liver disease
- Breastfeeding
- Blood dyscrasias (for example thrombocytopenia, leukopenia, significant anemia)
- Elevated liver transaminases
- History of intolerance or adverse event
- Hypersensitivity
- Interstitial pneumonitis or clinically significant pulmonary fibrosis
- Myelodysplasia
- Pregnancy or planning pregnancy (male or female)
- Renal impairment
- Significant drug interaction

Examples of Clinical Reasons to Avoid Treatment with Methotrexate, Cyclosporine:

- Alcoholism, alcoholic liver disease or other chronic liver disease
- Breastfeeding
- Drug interaction
- Cannot be used due to risk of treatment-related toxicity
- Pregnancy or planning pregnancy (male or female)
- Significant comorbidity prohibits use of systemic agents (examples include liver or kidney disease, blood dyscrasias, uncontrolled hypertension)

Examples of Contraindications to the Use of NSAIDs:

- Allergic-type reaction following aspirin or other NSAID administration
- Asthma

Pharmacy Prior Authorization

Clinical Guideline – Cytokines and Cell Adhesion Molecule (CAM) Antagonists

- Gastrointestinal bleeding
- History of intolerance or adverse event
- Urticaria
- Significant drug interaction

References:

1. Enbrel (etanercept) [package insert]. Thousand Oaks, CA; Immunex Corporation; Revised April 2021
2. Humira (adalimumab) [package insert]. North Chicago, IL; AbbVie Inc.; Revised. February 2021.
3. Cimzia (certolizumab) [package insert]. Smyrna, GA; UCB Inc.; Revised September 2019.
4. Remicade (infliximab) [package insert]. Horsham, PA; Janssen Biotech Inc.; Revised October 2021.
5. Simponi (golimumab) [package insert]. Horsham, PA; Janssen Biotech Inc.; Revised September 2019.
6. Orenzia (abatacept) [package insert]. Princeton, NJ; Bristol-Myers Squibb Company; Revised January 2022.
7. Xeljanz (tofacitinib citrate) [package insert]. NJ, NJ; Pfizer Labs; Revised December 2021.
8. Stelara (ustekinumab) [package insert]. Horsham, PA; Janssen Biotech, Inc. Revised December 2020.
9. Kineret (anakinra) [package insert]. Stockholm, Sweden; Swedish Orphan Biovitrum AB; Revised December 2020.
10. Actemra (tocilizumab) [package insert]. South San Francisco, CA; Genetec, Inc.; Revised February 2022.
11. Ilaris (canakinumab) [package insert]. East Hanover, NJ; Novartis Pharmaceuticals Corporation; Revised September 2020.
12. Siliq (brodalumab) [package insert]. Valeant Pharmaceuticals, Bridgewater, NJ, Revised April 2020.
13. Tremfya (guselkumab) [Package insert]. Janssen Biotech, Inc.; Horsham, PA; July 2020.
14. Arcalyst (rilonacept) [Package insert]. Kiniksa Pharmaceuticals, Ltd.; London, UK. Revised May 2021.
15. Kevzara (sarilumab) [Package insert]. Sanofi-Aventis US LLC and Regeneron Pharmaceuticals, Bridgewater, NJ. Revised April 2018.
16. Renflexis (infliximab-adba) [Package insert]. Organon & Co.; Jersey City, NJ. Revised January 2022.
17. Inflectra (infliximab-dyyb) [Package insert]. Celltrion, Inc.; Yeonsu-gu, Incheon. Revised March 2022.
18. Avsola (infliximab-axxq) [Package insert]. Amgen, Inc.; Thousand Oaks, CA. Revised September 2021.
19. Ilumya (tildrakizumab) [Package Insert]. Sun Pharmaceutical Industries, Inc.; Cranbury, NJ. Revised July 2020
20. Olumiant (baricitinib) [Package Insert] Eli Lilly, Indianapolis, IN. Revised December 2021.
21. Cosentyx (secukinumab) [Package insert]. Novartis Pharmaceuticals Corp. East Hanover, NJ. Revised December 2021.
22. Entyvio (vedolizumab) [Package insert]. Takeda, Deerfield, IL. Revised August 2021.
23. Taltz (ixekizumab) [Package insert]. Eli Lilly, Indianapolis, IL. Revised November 2021.
24. Tysabri (tofacitinib) [Package insert]. Biogen, Cambridge, MA. Revised December 2021.
25. Skyrizi (risankizumab) [Package insert]. AbbVie Inc, North Chicago, IL. Revised January 2022.
26. Rinvoq (upadacitinib) [Package insert]. AbbVie Inc, North Chicago, IL. Revised March 2022.
27. DRUGDEX System [Internet database]. Greenwood Village, CO: Thomson Micromedex. Updated periodically. Accessed on March 2022.
28. Levy-Clarke G, Jabs DA, Read RW, et al. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. *Ophthalmology* 2014; 121:785.
29. Singh JA, Saag KG, Bridges SL, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. *Arthritis Care Res.* 2016; 68(1):1-25.
30. Fraenkel L, Bathon JM, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. *Arthritis & Rheumatology*. Volume 73, Issue 7. p. 1108-1123.
31. Ringold S, Weiss PF, Beukelman T, et al. 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. *Arthritis Care Res.* 2013;65(10):1551-1563.
32. Weiss PF, Klein-Gitelman M, (2021). UpToDate. Oligoarticular juvenile idiopathic arthritis. In. E TePas (Ed.), <https://www.uptodate.com/contents/oligoarticular-juvenile-idiopathic-arthritis>. Accessed March 21, 2022.
33. Kimura Y. Systemic juvenile idiopathic arthritis: Treatment. Waltham, MA: Up-to-date; Last modified December 30, 2020. <https://www.uptodate.com/contents/systemic-juvenile-idiopathic-arthritis-treatment>. Accessed March 18, 2022.
34. National Institute for Health and Clinical Excellence (NICE). Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis. London (UK): National Institute for Health and Clinical Excellence (NICE); 2016 Dec. 58 p. (NICE technology appraisal guideline; no. 373).
35. Ward MM, Deodhar A, Akl EA, et al. American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. *Arthritis Care Res.* 2016;68(2):282-298.

Pharmacy Prior Authorization

Clinical Guideline – Cytokines and Cell Adhesion Molecule (CAM) Antagonists

36. Gossec L, Smolen JS, Ramiro S, et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. *Ann Rheum Dis*. 2015; 0:1-12.
37. National Institute for Health and Clinical Excellence (NICE). Psoriasis: the assessment and management of psoriasis. London (UK): National Institute for Health and Clinical Excellence (NICE); 2012 Oct. 61 p. (NICE clinical guideline; no. 153).
38. Feldman SR. Treatment of psoriasis. Waltham, MA: Up-to-date; Last modified. November 15, 2018. <http://www.uptodate.com/contents/treatment-of-psoriasis>. Accessed November 30, 2018.
39. Bousvaros A., Russell GH., Setty M. Management of severe or refractory ulcerative colitis in children and adolescents. Waltham, MA: Up-to-date; Last modified June 4, 2018. <https://www.uptodate.com/contents/management-of-severe-or-refractory-ulcerative-colitis-in-children-and-adolescents>. Accessed November 2018.
40. The Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults. *Am J Gastroenterology*. 2010;105:501-523.
41. Rubin DT, Ananthakrishnan AN, Siegel CA, et. al. ACG Clinical Guideline: Ulcerative Colitis in Adults. *Am J Gastroenterol*. 2019 Mar;114(3):384-413.
42. American Gastroenterological Association Institute Clinical Practice and Quality Management Committee. American Gastroenterological Association Institute Guideline on the use of thiopurines, methotrexate, and anti-TNF- α biologic drugs for the induction and maintenance of remission in inflammatory crohn's disease. *Gastroenterology*. 2013;145:1459–1463.
43. Lichtenstein GR, Loftus Jr EV, Isaacs KI, et al. ACG Clinical Guideline: Management of Crohn's Disease in Adults. *Am J Gastroenterol*. 2018;113:481-517.
44. Feuerstein J, Ho E, Shmidt E, et al. AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn's Disease. *Gastroenterology*. 2021;160:2496-2508.
45. Ingram JR. (2022) Hidradenitis suppurativa, Treatment, In A. Ofori (Ed), UpToDate. Retrieved March 21, 2022 from <https://www.uptodate.com/contents/hidradenitis-suppurativa-treatment>.
46. Alikhan A, Sayed C, Alavi A, et al. North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations Part II: Topical, intralesional, and systemic medical management. *J Am Acad Dermatol*. 2019; 81(1): 91-101.
47. Rosenbaum JT. Uveitis: Treatment. Waltham, MA: UpToDate; Last updated Nov 23, 2021. <https://www.uptodate.com/contents/uveitis-treatment>. Accessed March 21, 2022.
48. Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. *NEJM* 2009;360:2416-25.
49. Park W, Lee SJ, Yun J , et al: Comparison of the pharmacokinetics and safety of three formulations of infliximab (CT-P13, EU-approved reference infliximab and the US-licensed reference infliximab) in healthy subjects: a randomized, double-blind, three-arm, parallel-group, single-dose, Phase I study. *Expert Rev Clin Immunol* 2015; 11 Suppl 1:S25-S31.
PubMed Abstract: <http://www.ncbi.nlm.nih.gov/...>; PubMed Article: <http://www.ncbi.nlm.nih.gov/...>
50. Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0, November 2017, National Institutes of Health, National Cancer Institute. Available at: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf. Accessed December 19, 2018.
51. Angeles-Han ST., Ringold S., Beukelman T. et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis–Associated Uveitis. *Arthritis Care Res (Hoboken)*. 2019 Jun;71(6):703-716.
52. Ringold S, Angeles-Han ST, Beukelman T, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non-Systemic Polyarthritis, Sacroiliitis, and Enthesitis. *Arthritis Rheumatol*. 2019 Jun;71(6):846-863.
53. Ward MM, Deodhar A, Gensler LS, et. al. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. *Arthritis Rheumatol*. 2019 Oct;71(10):1599-1613.
54. Alikhan A, Sayed C, Alavi A, et. al. North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management. *J Am Acad Dermatol*. 2019 Jul;81(1):91-101.
55. Porter, D.L., Maloney, D.G., (2022). Cytokine release syndrome. In AG Rosmarin (Ed). Retrieved from: <https://www.uptodate.com/contents/cytokine-release-syndrome-crs>. Accessed March 21, 2022.
56. et al. Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. 2019. <https://doi.org/10.1016/j.jaad.2019.08.049>. Accessed December 4, 2019.
57. Singh JA, Guyatt J, Ogdie, A, 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. November 30, 2018 <https://doi.org/10.1177/2475530318812244>. Accessed December 4, 2019.

Last Update: 10/2016, 05/08/2017, 2/2018, 6/1/2018, 6/3/2019, 11/26/2019, 9/2021, 3/2022, 3/20/2023

Effective: 5/1/2023

Pharmacy Prior Authorization

Clinical Guideline – Cytokines and Cell Adhesion Molecule (CAM) Antagonists

- 58. Weiss PF. Diagnosis and treatment of enthesitis-related arthritis. *Adolesc Health Med Ther*. 2012;2012(3):67-74.
- 59. Chiabrando JG, Bonaventura A, Vecchié A, et al. Management of Acute and Recurrent Pericarditis. *J Am Coll Cardiol* 2020;75:76-92.
- 60. Amjevita (adalimumab-atto) [package insert]. Thousand Oaks, CA; Amgen; Revised. March 2023.